Current Challenges in the Management of Patients with Relapsed/Refractory Multiple Myeloma
Published: | Updated:
For patients with multiple myeloma (MM) who experience relapse, important advances in medical therapies in the past decade have doubled the duration of survival, mainly because of the effectiveness of novel agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid).[1]